Company Profile

OriGene is one of the industry’s largest suppliers of monoclonal antibodies to life science research and global IVD communities through the production of its TrueMAB™ and UltraMAB® Antibody product lines. In 2010 OriGene established one of the world’s largest high-throughput monoclonal antibody development and validation facilities at the Company’s WuXi, China location. Through its SDIX LLC subsidiary based in Newark, DE, the company has established its GMP and ISO13485 certified quality management system and expanded capacity for diagnostic antibody manufacturing. OriGene Technologies was founded as a research tool company focused on the creation of the largest commercial collection of full-length human cDNAs in a standard expression vector. The availability of the complete human genome sequence and the subsequent development of genome-based tools have enabled the identification of relevant drug targets through system biology approaches. OriGene's vision is to prepare comprehensive, genome wide research tools and technology platforms to enable scientists to study complete biological pathways, thus enabling a better understanding of disease mechanisms including cancer and stem cell research. OriGene Technologies uses high-throughput, genome wide approach to develop products for pharmaceutical, biotechnology, and academic research. The firm's flagship product is the cDNA clone collection, a searchable gene bank of over 30,000 human full-length TrueClone cDNA collection and over 25,000 TrueORF cDNA clones. From OriGene's TrueORF cDNA clones, the firm developed full length human proteins expressed in mammalian cells, ideal for functional studies. OriGene initiated the TrueMAB project to develop mouse monoclonal antibodies against protein antigens with the goal to develop protein assays for every human protein and now offers unique gene expression products such as TissueScan cancer tissue qPCR arrays and tissue biorepository for biomarker discovery and va